{"title":"Observation on the efficacy of intravitreal conbercept injection for macular edema secondary to retinal vein occlusion","authors":"Jing Li, Xiaoke Yao","doi":"10.3760/CMA.J.ISSN.2095-1477.2020.01.005","DOIUrl":null,"url":null,"abstract":"Objective \nTo observe the efficacy of intravitreal injection of conbercept for macular edema secondary to retinal vein occlusion (RVO). \n \n \nMethods \nA case-control retrospective study. The data of 52 patients with macular edema secondary to RVO from Jan. 2016 to Dec. 2018 in Shanxi Province Eye Hospital were analyzed. All patients were treated with intravitreal conbercept injection, dose of 0.5 mg or 0.05 mL, in the 3+ pro renata(PRN) project. The followed up time was 6 months. \n \n \nResults \nThe best corrected visual acuity (BCVA) at 1, 2, 3 and 6 months after treatment were better than that before treatment (t=13.010, 15.980, 7.530, 4.051, P<0.05). The thickness of central macula after treatment was lower than that before treatment (t=17.92, 12.32, 5.58, 0.41, P<0.05). During the treatment and follow-up, there was no serious complication such as vitreous hemorrhage, retinal detachment, persistent high intraocular pressure or endophthalmitis. \n \n \nConclusion \nIntravitreal injection of conbercept is effective in the treatment of macular edema secondary to RVO, which can improve vision and reduce macular edema. \n \n \nKey words: \nMacular edema, secondary; Conbercept, injection, intravitreal; Retinal vein occlusion","PeriodicalId":10126,"journal":{"name":"中华眼外伤职业眼病杂志","volume":"15 1","pages":"22-25"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华眼外伤职业眼病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.2095-1477.2020.01.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
To observe the efficacy of intravitreal injection of conbercept for macular edema secondary to retinal vein occlusion (RVO).
Methods
A case-control retrospective study. The data of 52 patients with macular edema secondary to RVO from Jan. 2016 to Dec. 2018 in Shanxi Province Eye Hospital were analyzed. All patients were treated with intravitreal conbercept injection, dose of 0.5 mg or 0.05 mL, in the 3+ pro renata(PRN) project. The followed up time was 6 months.
Results
The best corrected visual acuity (BCVA) at 1, 2, 3 and 6 months after treatment were better than that before treatment (t=13.010, 15.980, 7.530, 4.051, P<0.05). The thickness of central macula after treatment was lower than that before treatment (t=17.92, 12.32, 5.58, 0.41, P<0.05). During the treatment and follow-up, there was no serious complication such as vitreous hemorrhage, retinal detachment, persistent high intraocular pressure or endophthalmitis.
Conclusion
Intravitreal injection of conbercept is effective in the treatment of macular edema secondary to RVO, which can improve vision and reduce macular edema.
Key words:
Macular edema, secondary; Conbercept, injection, intravitreal; Retinal vein occlusion